Prostamax

What is it?

Prostamax is a Khavinson tetrapeptide for the prostate — part of the reproductive/hormone corner of the Khavinson short-peptide bioregulator family, alongside Testagen. Site tier is Anecdotal (4 studies, 0 human). The Lys-Glu-Asp-Pro sequence is anchored in a cited study title in the source ( 23221144), one of the few Khavinson-family sequences not carrying a flag on the sequence itself.

What does it do in my body?

Claimed mechanism: like the rest of the Khavinson family, Prostamax is proposed to act via gene-promoter binding in prostate tissue, framed as supporting prostate and urological health.

How can it help me?

• Where the science stands: Site tier Anecdotal (4 studies, 0 human) — all four are family chromatin-mechanism work, not prostate-outcome studies

The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.

Is it dangerous? What are the side effects?

No adverse-event data exists for Prostamax. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.

The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space, and a peptide marketed on an organ-specific claim it has no clinical outcome data for is an especially easy target for overselling. Third-party COA verification matters more here than for almost any other peptide class.

Regulatory status: Prostamax is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance.

Typical dosing

Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.

Educational purposes only — this reflects the Khavinson-school protocol convention shared across the family; it is not medical advice.

There is no dosing or cycling data specific to Prostamax, and no prostate-outcome human data exists to inform a protocol around. What exists is only the generic Khavinson-family cycle pattern: a short course of 10–20 days, repeated 2–3 times per year, with synthetic short peptides in the family generally dosed around ~100–200 mcg/day — but none of this has been validated for Prostamax specifically, let alone for a prostate-support outcome.

What should I avoid combining — and what's synergistic?

Prostamax doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.

How can I buy this?